Morusinol exerts anti-glioma activity by targeting the PI3K/AKT/mTOR signaling pathway
Naunyn-Schmiedeberg's Archives of Pharmacology · 2026
DOI: 10.1007/s00210-026-05070-w ↗Kurz gefasst
Fachartikel in der Zeitschrift Naunyn-Schmiedeberg's Archives of Pharmacology, 2026. Verfasst von Zhiyong Jin und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Nervous System Diseases, Xuzhou Medical University, Xuzhou, 221002, China. Hauptthemen laut MEDLINE: Glioma, TOR Serine-Threonine Kinases, Proto-Oncogene Proteins c-akt, Brain Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Basic Science (Natural Science) Research Project of Jiangsu Higher Education Institutions, XuZhou Medical University, National Natural Science Foundation of China.
Abstract (Originalsprache)
Glioma is a highly aggressive brain tumor with limited treatment options. Natural compounds offer promising therapeutic alternatives due to their safety and low toxicity. Morusinol, a flavonoid from Morus alba, exhibits anti-tumor effects in various cancers, but its role in glioma remains unknown. This study demonstrates that Morusinol significantly inhibits proliferation, migration, invasion, and colony formation of LN229 and U251 glioma cells, with IC50 values around 20 μM. It induces apoptosis by increasing ROS levels and modulating Bcl-2 family proteins and caspase-3 activation. Network pharmacology and molecular docking predict strong binding of Morusinol to key PI3K/AKT pathway components, including p110α, p85α, PDK1, and PTEN. Western blotting confirms that Morusinol suppresses AKT and mTOR phosphorylation, indicating pathway inhibition. Importantly, co-treatment with UCL-TRO-1938, a p110α activator, partially reverses Morusinol-induced suppression of AKT phosphorylation and cell proliferation, supporting target specificity. These results indicate that Morusinol exerts potent anti-glioma effects primarily through inhibition of the PI3K/AKT/mTOR signaling pathway. Our findings highlight Morusinol as a promising natural agent for glioma therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Nervous System Diseases, Xuzhou Medical University, Xuzhou, 221002, China.
- Institute of Nervous System Diseases, Xuzhou Medical University, Xuzhou, 221002, China. rtyu@xzhmu.edu.cn.
- Department of Neurosurgery, Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221002, China. rtyu@xzhmu.edu.cn.
Förderung
- Basic Science (Natural Science) Research Project of Jiangsu Higher Education Institutions
- XuZhou Medical University
- National Natural Science Foundation of China
- Jiangsu Provincial Medical Key Discipline (Laboratory)
Zitieren
APA
Jin, Z., Xiao, C., Ma, S., Li, G., Zhu, M., Zhang, F., Zhang, H., & Yu, R. (2026). Morusinol exerts anti-glioma activity by targeting the PI3K/AKT/mTOR signaling pathway. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-026-05070-w
Vancouver
Jin Z, Xiao C, Ma S, Li G, Zhu M, Zhang F, et al. Morusinol exerts anti-glioma activity by targeting the PI3K/AKT/mTOR signaling pathway. Naunyn-Schmiedeberg's Archives of Pharmacology. 2026. doi:10.1007/s00210-026-05070-w
BibTeX
@article{Jin2026,
author = {Jin, Zhiyong and Xiao, Changzhou and Ma, Sicheng and Li, Gang and Zhu, Mengyao and Zhang, Feifan and Zhang, Hanyu and Yu, Rutong},
title = {Morusinol exerts anti-glioma activity by targeting the PI3K/AKT/mTOR signaling pathway},
journal = {Naunyn-Schmiedeberg's Archives of Pharmacology},
year = {2026},
doi = {10.1007/s00210-026-05070-w}
}
EUVIMED